Publicis picks up Sanofi vaccines PR

Share this article:
Sanofi Pasteur has handed the communications business on several key vaccines, including the prospective launch of Pentacel, to Publicis Public Relations.

The move, first reported in PRWeek, follows a three-month, four-way review. Pentacel and Adacel will be handled jointly by Publicis' MS&L and Publicis Consultants PR.

Five-in-one Pentacel, which protects against tetanus, diphtheria, pertussis, polio and flu in children, got the green light from an FDA advisory panel in January, and is expected to win approval this month. The vaccine would mean fewer shots for infants and children under 18 months—from the current 23 to 18.

“We believe the marketplace is interested in combination vaccines because of all the vaccines on children's schedules,” Sanofi Pasteur PR manager Susan Watkins told PRWeek. “We are looking forward to hearing from the FDA, and Publicis will be helping us along the way.”

Adacel, approved in 2005, protects adults and adolescents against tetanus, diphtheria and pertussis.
While infants are particularly vulnerable to pertussis—commonly called whooping cough— cases have been on the rise among adolescents and adults in recent years, with infections occurring as childhood immunizations wear off.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...